Challenging the Status-Quo: Cardiorenal Protection with SGLT-2 Inhibitors in T2DM and Beyond—Expert Debate and Discussions
During this activity, multidisciplinary experts discuss the evidence with SGLT-2 inhibitors in reducing cardiorenal risk in patients with and without T2DM, as well as offer additional clinical pearls about their application across specialties.
This interactive monograph is organized in an easily digestible format, containing a mix of visuals, audio, video, resources, patient cases, as well as news articles and publications, in order to better facilitate the interpretation of the journey of SGLT-2 inhibitors across trials and to patient care.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Review the underlying links between CVD, HF, DKD, and T2DM and how the potential mechanisms of action of SGLT-2 inhibitors help address cardiorenal risk in T2DM and beyond.
- Summarize recently-concluded and ongoing studies about the efficacy and safety of SGLT-2 inhibitors in addressing cardiometabolic risk in patients with and without T2DM.
- Discuss practical approaches and strategies, including multidisciplinary collaboration, for the use of SGLT-2 inhibitors in T2DM patients with cardiorenal risk.
- Develop individualized treatment regimens based on the latest evidence and guideline recommendations in order to address cardio-renal risk in patients with T2DM.
George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Dr. Bakris discloses the following:
Consulting Fees: Merck, Novo Nordisk, DiaMedica, Bayer, Relypsa
Contracted Research: Bayer, Novo Nordisk, Vascular Dynamics-all to UC
Robert H. Eckel, MD
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
University of Colorado Anschutz Medical Campus
Past President, American Heart Association
President, Medicine and Science, American Diabetes Association
Dr. Eckel discloses the following:
Consulting Fees: Sanofi/Regeneron, Novo Nordisk
Stephen D. Wiviott, MD, FACC
Associate Professor of Medicine, Harvard Medical School
Executive Director Clinical Trials Office, Partners HealthCare
Dr. Wiviott discloses the following:
Consulting Fees: ARENA, AstraZeneca, Aegerion, Allergan, Angelmed, Boehringer-Ingelheim, Boston Clinical Research Institute, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Icon Clinical, Janssen, Lexicon, Merck, Servier, St Jude Medical, Xoma.
Contracted Research: Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Merck and Sanofi-Aventis.
Other: Spouse is an employee of Merck
Dr. Wiviott is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, Zora Biosciences
This activity is supported by an educational grant from AstraZeneca.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Cardiometabolic Health Congress. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 CreditTM Designation Statement
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
ANCC Contact Hour
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
2.25 contact hours may be earned for successful completion of this activity.
Continuing Pharmacy Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is assigned ACPE Universal Activity #0797-9999-20-121-H01-P. This program is designated for up to 2.25 contact hours (0.225 CEUs) of continuing pharmacy education credit.
CONTINUING DIETICIAN EDUCATION
This program offers 2.25 CPEUs for dieticians.
ACCREDITED PROVIDER DISCLOSURE
Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
CONFLICT OF INTEREST DISCLOSURE POLICY
Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Annenberg Center for Health Sciences at Eisenhower policy. Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period November 24, 2020 through November 24, 2021, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.annenberg.net.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 2.25 ACPE Pharmacy
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC
- 2.25 CDE
- 2.25 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.